Methicillin Resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. bioMérieux, a world leader in the field of in vitro diagnostics, today launched NucliSENS EasyQ® MRSA, a new automated test for Methicillin Resistant Staphylococcus aureus (MRSA), one of the leading causes of healthcare-associated infections. NucliSENS EasyQ MRSA is CE marked and bioMérieux will be submitting for 510(k) approval with the U.S. Food and Drug Administration in the first half of 2010.
2nd World HAI Forum: Experts Discuss Looming Threats to Patient Safety
Newly evolved enzymes make some bacteria resistant to all common antibiotics Healthcare workers slow to receive flu vaccines Countries not doing enough to combat “superbugs” About 7 million Healthcare-Associated Infections (HAIs) in the U.S. and Europe each yearAccording to a meeting of over 60 infectious disease experts, the global medical community must act on three imminent threats to patients across the world. First threat: common bacteria, such as Escherichia coli (E. coli) are now producing enzymes which make the bacteria capable of de-activating all but the antibiotics that specialists reserve as a last line of defense. Second threat: healthcare workers themselves may be contributing to the spread of infections by failing to get flu vaccinations and, in some countries, coming to work when they are ill rather than taking sick days. Third threat: Health ministries are failing to adopt proven health policies that could limit the spread of infections in hospitals and other healthcare establishments.
bioMérieux Launches VIDAS® EBV, a New Test for the Diagnosis of Infectious Mononucleosis
bioMérieux, a world leader in the field of in vitro diagnostics, today launched VIDAS® EBV for the detection of the Epstein-Barr virus (EBV). This virus causes 80% of cases of infectious mononucleosis, which is often known as “the kissing disease” because it is transmitted through saliva.
bioMérieux Launches Molecular Biology Test, NucliSENS EasyQ® HIV-1 v2.0, for Improved Care of Patients with HIV
New test can be used with the first CE marked Dry Blood Spot sample collection technique for viral load monitoring, bringing testing to patients in remote locationsbioMérieux, a world leader in the field of in vitro diagnostics, presented the latest addition to its HIV testing offer at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). NucliSENS EasyQ® HIV-1 v2.0 is a test able to detect even very low viral load levels in AIDS patients, offering one of the highest degrees of sensitivity available today.
bioMérieux: Enhancing the Productivity of Microbiology Laboratories with the LeanSigma® Method
bioMérieux, a world leader in the field of in vitro diagnostics, is building upon its Full Microbiology Lab Automation™ (FMLA) concept by offering a new tool to its customers, LeanSigma® - today’s most recognized process and flow improvement methodology.
2009 ESCMID/bioMérieux Research Grant in Clinical Microbiology Winner Conducting Research on Major Cause of Healthcare-Associated Infections
bioMérieux, a world leader in in vitro diagnostics, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announce the recipient of their 2009 Research Grant, which recognizes excellence and major contributions to progress in the field of clinical microbiology by a young scientist from Eastern Europe.